TREATMENT OF C-MYC/BCL2 DOUBLE EXPRESSER DLBCL WITH R-CHOP CHEMOIMMUNOTHERAPY: AN AUSTRALIAN SINGLE CENTRE EXPERIENCE

被引：0
|
作者：
Ng, T. F. [1 ,2 ]
Whiteside, A. [3 ]
Rose, H. [1 ]
Kipp, D. [1 ]
Tawfik, B. [3 ]
Campbell, P. [1 ,4 ]
机构：
[1] Univ Hosp Geelong, Clin Haematol, Geelong, Vic, Australia
[2] Fiona Stanley Hosp, Haematol, Perth, WA, Australia
[3] St John God Pathol, Anat Pathol, Geelong, Vic, Australia
[4] Deakin Univ, Sch Med, Geelong, Vic, Australia
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1724
引用
收藏
页码：701 / 701
页数：1
相关论文
共 37 条
  • [1] Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP
    Johnson, Nathalie A.
    Connors, Joseph M.
    Ben-Neriah, Susana
    Rogic, Sanja
    Savage, Kerry Joanne
    Steidl, Christian
    Horsman, Douglas E.
    Slack, Graham W.
    Sehn, Laurie
    Chan, Wing-Chung
    Iqbal, Javeed
    Meyer, Paul N.
    Lenz, Georg
    Wright, George W.
    Rimsza, Lisa M.
    Valentino, Carlo
    Brunhoeber, Patrick
    Grogan, Thomas
    Braziel, Rita M.
    Cook, James
    Tubbs, Raymond R.
    Weisenburger, Dennis D.
    Campo, Elias
    Rosenwald, Andreas
    Ott, German
    Delabie, Jan
    Jaffe, Elaine
    Staudt, Louis M.
    Gascoyne, Randy D.
    BLOOD, 2010, 116 (21) : 836 - 836
  • [2] Impact of the Double Expression of MYC and BCL2 on Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma Following R-CHOP Chemoimmunotherapy
    Suzuki, Tomotaka
    Maruyama, Dai
    Maeshima, Akiko Miyagi
    Tajima, Kinuko
    Ito, Yuta
    Hatta, Shunsuke
    Yuda, Sayako
    Makita, Shinichi
    Fukuhara, Suguru
    Munakata, Wataru
    Suzuki, Tatsuya
    Taniguchi, Hirokazu
    Kobayashi, Yukio
    Izutsu, Koji
    Tobinai, Kensei
    BLOOD, 2017, 130
  • [3] Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
    Johnson, Peter W. M.
    Balasubramanian, Sriram
    Hodkinson, Brendan
    Shreeve, S. Martin
    Sun, Steven
    Srinivasan, Srimathi
    Steele, Andrew J.
    Vermeulen, Jessica
    Sehn, Laurie H.
    Wilson, Wyndham H.
    BLOOD ADVANCES, 2023, 7 (10) : 2008 - 2017
  • [4] Clinical impact of BCL2, BCL6 and c-MYC rearrangements in diffuse large B cell lymphoma patients treated with R-CHOP
    Copie-Bergman, C.
    Baia, M.
    Molina, T. J.
    Mounier, N.
    Briere, J.
    Leroy, K.
    Tilly, H.
    Gisselbrecht, C.
    Haioun, C.
    Coiffier, B.
    Gaulard, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 106 - 106
  • [5] R-CHOP in the treatment of DLBCL: Single institution experience from north India.
    Vaid, AK
    Gupta, S
    Doval, DC
    Talwar, V
    Gupta, R
    Sharma, JB
    Chaturvedi, AK
    Prakesh, N
    BLOOD, 2005, 106 (11) : 273B - 273B
  • [6] A prospective study to determine survival outcome to CHOP-based therapy in patients with double expresser DLBCL: Single centre experience from India
    Asati, V.
    Lakshmaiah, K. C.
    Babu, K. Govind
    Lokanath, D.
    Jacob, L. A.
    Babu, M. C. Suresh
    Lokesh, K. N.
    Rajeev, L. K.
    Rudresha, A. H.
    Smitha, S. C.
    Giri, G. V.
    Koppaka, D.
    Anand, A.
    Chethan, R.
    Chaudhuri, T.
    Patidar, R.
    Goyal, A.
    Premalata, C. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma
    Xu, Jie
    Liu, Jing-Lan
    Medeiros, L. Jeffrey
    Huang, Wenting
    Khoury, Joseph D.
    McDonnell, Timothy J.
    Tang, Guilin
    Schlette, Ellen
    Yin, C. Cameron
    Bueso-Ramos, Carlos E.
    Lin, Pei
    Li, Shaoying
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (04) : 336 - 343
  • [8] Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial
    Johnson, Peter
    Balasubramanian, Sriram
    Hodkinson, Brendan
    Schaffer, Michael
    Parisi, Lori
    Shreeve, S. Martin
    Sun, Steven
    Vermeulen, Jessica
    Sehn, Laurie H.
    Staudt, Louis
    Younes, Anas
    Wilson, Wyndham
    BLOOD, 2019, 134
  • [9] The Role of MYC and BCL-2 Double Expression the in DLBCL Patients with Advanced Stage and Elevated LDH Who Received Upfront ASCT after R-CHOP
    Kim, Yu Ri
    Yoon, Sun Och
    Kim, Soo-Jeong
    Cheong, June-Won
    Lee, Hyewon
    Chung, Haerim
    Lee, Jung Yeon
    Jang, Ji Eun
    Kim, Yundeok
    Yang, Woo-Ick
    Min, Yoo-Hong
    Kim, Jin Seok
    BLOOD, 2016, 128 (22)
  • [10] Randomized phase II/III study of R-CHOP plus /- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701
    Abramson, Jeremy S.
    Geyer, Susan Michelle
    Pederson, Levi D.
    Giri, Sharmila
    Hsi, Eric D.
    Little, Richard F.
    Gore, Steven
    Landsburg, Daniel J.
    Cherng, Hua-Jay Jeffery
    Kahl, Brad S.
    Mehta-Shah, Neha
    Dinner, Shira
    Friedberg, Jonathan W.
    Bartlett, Nancy L.
    Leonard, John Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1234